Cell Therapeutics, the Seattle-based biotech company, said today that Italian securities regulators will allow trading in its shares to resume in Italy on Feb. 18 after it issued a statement detailing its finances. This means the company expects (NASDAQ: [[ticker:CTIC]]) to re-start trading in the U.S. on Feb. 18 as well. The company has run dangerously low on cash, with only enough money to run through February, as we described last week. Cell Therapeutics’ last traded in the U.S. at 8 cents.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
